Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 CERK inhibition might be a good potential therapeutic target for diseases.

× No keyword cloud information.

4 in total

1. The ceramide kinase inhibitor NVP-231 inhibits breast and lung cancer cell proliferation by inducing M phase arrest and subsequent cell death.

Authors: Oleksandr Pastukhov; Stephanie Schwalm; Uwe Zangemeister-Wittke; Doriano Fabbro; Frederic Bornancin; Lukasz Japtok; Burkhard Kleuser; Josef Pfeilschifter; Andrea Huwiler
Journal: Br J Pharmacol Date: 2014-12 Impact factor: 8.739

2. Ceramide kinase promotes tumor cell survival and mammary tumor recurrence.

Authors: Ania W Payne; Dhruv K Pant; Tien-Chi Pan; Lewis A Chodosh
Journal: Cancer Res Date: 2014-08-27 Impact factor: 12.701

3. Ceramide kinase contributes to proliferation but not to prostaglandin E2 formation in renal mesangial cells and fibroblasts.

Authors: Oleksandr Pastukhov; Stephanie Schwalm; Isolde Römer; Uwe Zangemeister-Wittke; Josef Pfeilschifter; Andrea Huwiler
Journal: Cell Physiol Biochem Date: 2014-06-16

4. New signalling pathway involved in the anti-proliferative action of vitamin D₃ and its analogues in human neuroblastoma cells. A role for ceramide kinase.

Authors: Francesca Bini; Alessia Frati; Mercedes Garcia-Gil; Chiara Battistini; Maria Granado; Maria Martinesi; Marco Mainardi; Eleonora Vannini; Federico Luzzati; Matteo Caleo; Paolo Peretto; Antonio Gomez-Muñoz; Elisabetta Meacci
Journal: Neuropharmacology Date: 2012-05-08 Impact factor: 5.250

4 in total

3 in total

1. CERK might contribute to inflammatory pain; Comments on Yu WL, Sun. Y (2015). CERK inhibition might be a good potential therapeutic target for diseases. Br J Pharmacol 172: 2165.

Authors: Jin-lu Huang; Yan Huo; Li-li Wan; Quan-jun Yang; Jie Li; Cheng Guo
Journal: Br J Pharmacol Date: 2016-04 Impact factor: 8.739

Review 2. The Role of Sphingosine-1-Phosphate and Ceramide-1-Phosphate in Inflammation and Cancer.

Authors: Nitai C Hait; Aparna Maiti
Journal: Mediators Inflamm Date: 2017-11-15 Impact factor: 4.711

3. Unraveling the molecular heterogeneity in type 2 diabetes: a potential subtype discovery followed by metabolic modeling.

Authors: Maryam Khoshnejat; Kaveh Kavousi; Ali Mohammad Banaei-Moghaddam; Ali Akbar Moosavi-Movahedi
Journal: BMC Med Genomics Date: 2020-08-24 Impact factor: 3.063

3 in total